Cardiovascular complications after transplantation: Treatment options in solid organ recipients

Transplantation Reviews

Volumn 28, Issue 2, 2014, Pages 47-55

  Gillis, Keith A ^a   Patel, Rajan K ^a   Jardine, Alan G ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; EZETIMIBE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LIPOPROTEIN A; TRIACYLGLYCEROL;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL (TOPIC); CORONARY ARTERY DISEASE; DIABETES MELLITUS; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; GRAFT FAILURE; HEART FAILURE; HEART TRANSPLANTATION; HEMODIALYSIS PATIENT; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; INSULIN RESISTANCE; KIDNEY DYSFUNCTION; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; LIFESTYLE; LIPOPROTEIN BLOOD LEVEL; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; NEW ONSET DIABETES AFTER TRANSPLANTATION; ORGAN TRANSPLANTATION; OXIDATIVE STRESS; PANCREAS TRANSPLANTATION; PATHOPHYSIOLOGY; POSTOPERATIVE COMPLICATION; PROTEINURIA; REVIEW; SOLID ORGAN TRANSPLANTATION; SUDDEN DEATH; SURGICAL MORTALITY; SURGICAL RISK; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; CARDIOVASCULAR DISEASES; CORONARY DISEASE; DEATH, SUDDEN, CARDIAC; FEMALE; GRAFT SURVIVAL; INCIDENCE; MALE; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; RISK ASSESSMENT; SURVIVAL;

CARDIOVASCULAR DISEASES; CORONARY DISEASE; DEATH, SUDDEN, CARDIAC; FEMALE; GRAFT SURVIVAL; HEART FAILURE; HUMANS; INCIDENCE; KIDNEY TRANSPLANTATION; MALE; ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; RISK ASSESSMENT; SURVIVAL ANALYSIS;

EID: 84897051708     PISSN: 0955470X     EISSN: 15579816     Source Type: Journal    
DOI: 10.1016/j.trre.2013.12.001     Document Type: Review

References (123)

1. Foley R.N., Parfrey P.S., Sarnak M.J. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998, 32:S112-S119.
2. Baigent C., Burbury K., Wheeler D. Premature cardiovascular disease in chronic renal failure. Lancet 2000, 356:147-152.
3. Holdaas H., Fellstrom B., Jardine A.G., et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003, 361:2024-2031.
4. Holdaas H., Fellstrom B., Cole E., et al. Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. Am J Transplant 2005, 5:2929-2936.
5. Israni A.K., Snyder J.J., Skeans M.A., et al. Predicting coronary heart disease after kidney transplantation: Patient Outcomes in Renal Transplantation (PORT) Study. Am J Transplant 2010, 10:338-353.
6. Holdaas H., Fellstrom B., Cole E., et al. Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study.[Erratum appears in Am J Transplant. 2006 Aug;6(8):1986]. American Journal of Transplantation 2005, 5(12):2929-2936.
7. Ponticelli C., Cucchiari D., Graziani G. Hypertension in kidney transplant recipients. Transpl Int 2011, 24:523-533.
8. Hillebrand U., Suwelack B.M., Loley K., et al. Blood pressure, antihypertensive treatment, and graft survival in kidney transplant patients. Transpl Int 2009, 22:1073-1080.
9. Walker B.R. Glucocorticoids and cardiovascular disease. Eur J Endocrinol 2007, 157:545-559.
10. Kasiske B.L., Chakkera H.A., Roel J. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol 2000, 11:1735-1743.
11. Abbott K.C., Hypolite I.O., Hshieh P., et al. Hospitalized congestive heart failure after renal transplantation in the United States. Ann Epidemiol 2002, 12:115-122.
12. Rigatto C., Parfrey P., Foley R., et al. Congestive heart failure in renal transplant recipients: risk factors, outcomes, and relationship with ischemic heart disease. J Am Soc Nephrol 2002, 13:1084-1090.
13. Jardine A.G., Fellstrom B., Logan J.O., et al. Cardiovascular risk and renal transplantation: post hoc analyses of the Assessment of Lescol in Renal Transplantation (ALERT) Study. Am J Kidney Dis 2005, 46:529-536.
14. Soveri I., Holdaas H., Jardine A., et al. Renal transplant dysfunction - importance quantified in comparison with traditional risk factors for cardiovascular disease and mortality. Nephrol Dial Transplant 2006, 21:2282-2289.
15. Oberbauer R., Segoloni G., Campistol J.M., et al. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48months after transplantation. Transpl Int 2005, 18:22-28.
16. Vanrenterghem Y., Bresnahan B., Campistol J., et al. Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies). Transplantation 2011, 91:976-983.
17. Larsen C.P., Grinyo J., Medina-Pestana J., et al. Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies. Transplantation 2010, 90:1528-1535.
18. Gaston R.S., Kasiske B.L., Fieberg A.M., et al. Use of cardioprotective medications in kidney transplant recipients. Am J Transplant 2009, 9:1811-1815.
19. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009, 9:S1-S155.
20. Midtvedt K., Ihlen H., Hartmann A., et al. Reduction of left ventricular mass by lisinopril and nifedipine in hypertensive renal transplant recipients: a prospective randomized double-blind study. Transplantation 2001, 72:107-111.
21. Heinze G., Mitterbauer C., Regele H., et al. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J Am Soc Nephrol 2006, 17:889-899.
22. Opelz G., Zeier M., Laux G., et al. No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme inhibitors or angiotensin II Type 1 receptor blockers: a collaborative transplant study report. J Am Soc Nephrol 2006, 17:3257-3262.
23. Philipp T., Martinez F., Geiger H., et al. Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients: results from SECRET. Nephrol Dial Transplant 2010, 25:967-976.
24. Paoletti E., Bellino D., Marsano L., et al. Effects of ACE inhibitors on long-term outcome of renal transplant recipients: a randomized controlled trial. Transplantation 2013, 95:889-895.
25. Opelz G., Dohler B. Improved long-term outcomes after renal transplantation associated with blood pressure control. Am J Transplant 2005, 5:2725-2731.
26. Patel R.K., et al. Renal transplantation is not associated with regression of left ventricular hypertrophy: a magnetic resonance study. Clin J Am Soc Nephrol 2008, 3:1807-1811.
27. Paoletti E., Ratto E., Bellino D., et al. Effect of early conversion from CNI to sirolimus on outcomes in kidney transplant recipients with allograft dysfunction. J Nephrol 2012, 25:709-718.
28. Wong W., Tolkoff-Rubin N., Delmonico F.L., et al. Analysis of the cardiovascular risk profile in stable kidney transplant recipients after 50% cyclosporine reduction. Clin Transpl 2004, 18:341-348.
29. Pestana J.O., Grinyo J.M., Vanrenterghem Y., et al. Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys. Am J Transplant 2012, 12:630-639.
30. Pascual J., Zamora J., Galeano C., et al. Steroid avoidance or withdrawal for kidney transplant recipients. Cochrane Database Syst Rev 2009, 1:CD005632.
31. Vincenti F., Charpentier B., Vanrenterghem Y., et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010, 10:535-546.
32. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010, 376:1903-1909.
33. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24months. Hypertension 2011, 57:911-917.
34. Holdaas H. Clinical lipidology: a compansion to Braunwald's heart disease; special populations: transplant recipients 2009, Saunders.
35. Tse K.C., Lam M.F., Yip P.S., et al. A long-term study on hyperlipidemia in stable renal transplant recipients. Clin Transplant 2004, 18:274-280.
36. Ghanem H., van den Dorpel M.A., Weimar W., et al. Increased low density lipoprotein oxidation in stable kidney transplant recipients. Kidney Int 1996, 49:488-493.
37. Kasiske B.L., Guijarro C., Massy Z.A., et al. Cardiovascular disease after renal transplantation. J Am Soc Nephrol 1996, 7:158-165.
38. Kasiske B.L. Hyperlipidemia in patients with chronic renal disease. Am J Kidney Dis 1998, 32:S142-S156.
39. White M., Haddad H., Leblanc M.H., et al. Conversion from cyclosporine microemulsion to tacrolimus-based immunoprophylaxis improves cholesterol profile in heart transplant recipients with treated but persistent dyslipidemia: the Canadian multicentre randomized trial of tacrolimus vs cyclosporine microemulsion. J Heart Lung Transplant 2005, 24:798-809.
40. Blum C.B. Effects of sirolimus on lipids in renal allograft recipients: an analysis using the Framingham risk model. Am J Transplant 2002, 2:551-559.
41. Association T.R. Post operative care of the kidney transplant recipient 2011.
42. Cosio F.G., Pesavento T.E., Pelletier R.P., et al. Patient survival after renal transplantation III: the effects of statins. Am J Kidney Dis 2002, 40:638-643.
43. Holdaas H., Fellstrom B., Jardine A.G., et al. Beneficial effect of early initiation of lipid-lowering therapy following renal transplantation. Nephrol Dial Transplant 2005, 20:974-980.
44. Holdaas H., Fellstrom B., Cole E., et al. Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study.[Erratum appears in Am J Transplant. 2006 Aug;6(8):1986]. Am J Transplant 2005, 5:2929-2936.
45. Baigent C., Landray M.J., Reith C., et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011, 377:2181-2192.
46. Wissing K.M., Unger P., Ghisdal L., et al. Effect of atorvastatin therapy and conversion to tacrolimus on hypercholesterolemia and endothelial dysfunction after renal transplantation. Transplantation 2006, 82:771-778.
47. Gagne C., Bays H.E., Weiss S.R., et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002, 90:1084-1091.
48. Kastelein J.J.P., Akdim F., Stroes E.S.G., et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008, 358:1431-1443.
49. Taylor A.J., Villines T.C., Stanek E.J., et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009, 361:2113-2122.
50. Woodward R.S., Schnitzler M.A., Baty J., et al. Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients. Am J Transplant 2003, 3:590-598.
51. Cole E.H., Johnston O., Rose C.L., et al. Impact of acute rejection and new-onset diabetes on long-term transplant graft and patient survival. Clin J Am Soc Nephrol 2008, 3:814-821.
52. Cosio F.G., Pesavento T.E., Osei K., et al. Post-transplant diabetes mellitus: increasing incidence in renal allograft recipients transplanted in recent years. Kidney Int 2001, 59:732-737.
53. Kasiske B.L., Snyder J.J., Gilbertson D., et al. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003, 3:178-185.
54. Cosio F.G., Kudva Y., van der Velde M., et al. New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation. Kidney Int 2005, 67:2415-2421.
55. Rakel A., Karelis A.D. New-onset diabetes after transplantation: risk factors and clinical impact. Diabetes Metab 2011, 37:1-14.
56. Vincenti F., Friman S., Scheuermann E., et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 2007, 7:1506-1514.
57. Sigal N.H., Dumont F.J. Cyclosporin A, FK-506, and rapamycin: pharmacologic probes of lymphocyte signal transduction. Annu Rev Immunol 1992, 10:519-560.
58. Webster A.C., Woodroffe R.C., Taylor R.S., et al. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. BMJ 2005, 331:810-821.
59. Hjelmesaeth J., Hartmann A., Kofstad J., et al. Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. Transplantation 1997, 64:979-983.
60. Wilkinson A., Davidson J., Dotta F., et al. Guidelines for the treatment and management of new-onset diabetes after transplantation. Clin Transplant 2005, 19:291-298.
61. WHO Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia 2006.
62. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2003, 26:s5-s20.
63. Montori V.M., Basu A., Erwin P.J., et al. Posttransplantation diabetes: a systematic review of the literature. Diabetes Care 2002, 25:583-592.
64. Bee Y.M., Tan H.C., Tay T.L., et al. Incidence and risk factors for development of new-onset diabetes after kidney transplantation. Ann Acad Med Singapore 2011, 40:160-167.
65. Tuomilehto J., Lindström J., Eriksson J.G., et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001, 344:1343-1350.
66. NICE N.I.f.H.a.C.E. Type 2 diabetes: the management of type 2 diabetes 2009.
67. SIGN Management of diabetes: a national clinical guideline 2010.
68. ADA Clinical practice recommendations 2013.
69. Nissen S.E., Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356:2457-2471.
70. Werzowa J., Hecking M., Haidinger M., et al. Vildagliptin and pioglitazone in patients with impaired glucose tolerance after kidney transplantation: a randomized, placebo-controlled clinical trial. Transplantation 2013, 95:456-462.
71. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545-2559.
72. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560-2572.
73. Hecking M., Haidinger M., Doller D., et al. Early basal insulin therapy decreases new-onset diabetes after renal transplantation. J Am Soc Nephrol 2012, 23:739-749.
74. Weiner D.E., Carpenter M.A., Levey A.S., et al. Kidney function and risk of cardiovascular disease and mortality in kidney transplant recipients: the FAVORIT trial. Am J Transplant 2012, 12:2437-2445.
75. Oberbauer R., Kreis H., Johnson R.W., et al. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study. Transplantation 2003, 76:364-370.
76. Vitko S., Tedesco H., Eris J., et al. Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies. Am J Transplant 2004, 4:626-635.
77. Budde K., Becker T., Arns W., et al. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet 2011, 377:837-847.
78. Mjornstedt L., Sorensen S.S., von Zur Muhlen B., et al. Improved renal function after early conversion from a calcineurin inhibitor to everolimus: a randomized trial in kidney transplantation. Am J Transplant 2012, 12:2744-2753.
79. Schena F.P., Pascoe M.D., Alberu J., et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009, 87:233-242.
80. Hernández D., Pérez G., Marrero D., et al. Early association of low-grade albuminuria and allograft dysfunction predicts renal transplant outcomes. Transplantation 2012, 93:297-303. 10.1097/TP.0b013e31823ec0a7.
81. Stevens K.K., Patel R.K., Methven S., et al. Proteinuria and outcome after renal transplantation: ratios or fractions?. Transplantation 2013, 96:65-69. 10.1097/TP.0b013e318295852c.
82. Assessment for renal transplantation 2008.
83. Kasiske B.L., Klinger D. Cigarette smoking in renal transplant recipients. J Am Soc Nephrol 2000, 11:753-759.
84. Painter P.L., Hector L., Ray K., et al. A randomized trial of exercise training after renal transplantation. Transplantation 2002, 74:42-48.
85. Painter P.L., Hector L., Ray K., et al. Effects of exercise training on coronary heart disease risk factors in renal transplant recipients. Am J Kidney Dis 2003, 42:362-369.
86. Davignon J., Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 2004, 109:III27-III32.
87. Zoccali C., Bode-Boger S., Mallamaci F., et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001, 358:2113-2117.
88. Passauer J., Bussemaker E., Lassig G., et al. Kidney transplantation improves endothelium-dependent vasodilation in patients with endstage renal disease. Transplantation 2003, 75:1907-1910.
89. Morris S.T., McMurray J.J., Spiers A., et al. Impaired endothelial function in isolated human uremic resistance arteries. Kidney Int 2001, 60:1077-1082.
90. Abedini S., Meinitzer A., Holme I., et al. Asymmetrical dimethylarginine is associated with renal and cardiovascular outcomes and all-cause mortality in renal transplant recipients. Kidney Int 2010, 77:44-50.
91. Gratton J.P., Bernatchez P., Sessa W.C. Caveolae and caveolins in the cardiovascular system. Circ Res 2004, 94:1408-1417.
92. Weiner D.E., Carpenter M.A., Levey A.S., et al. Kidney function and risk of cardiovascular disease and mortality in kidney transplant recipients: the FAVORIT trial. American Journal of Transplantation 2012, 12(9):2437-2445.
93. Stevens K.K., Morgan I.R., Patel R.K., et al. Serum phosphate and outcome at one year after deceased donor renal transplantation. Clin Transplant 2011, 25:E199-E204.
94. Chung B.H., Kang S.H., Hwang H.S., et al. Clinical significance of early-onset hyperuricemia in renal transplant recipients. Nephron Clin Pract 2011, 117:c276-c283.
95. Rigatto C. Anemia, renal transplantation, and the anemia paradox. Semin Nephrol 2006, 26:307-312.
96. Heinze G., Kainz A., Hörl W.H., et al. Mortality in renal transplant recipients given erythropoietins to increase haemoglobin concentration: cohort study. BMJ 2009, 339.
97. Lentine K.L., Villines T.C., Xiao H., et al. Cardioprotective medication use after acute myocardial infarction in kidney transplant recipients. Transplantation 2011, 91:1120-1126.
98. Patel R.K., Mark P.B., Johnston N., et al. Prognostic value of cardiovascular screening in potential renal transplant recipients: a single-center prospective observational study. Am J Transplant 2008, 8:1673-1683.
99. Kasiske B.L., et al. Design considerations and feasibility for a clinical trial to examine coronary screening before kidney transplantation (COST). Am J Kidney Dis 2011, 57:908-916.
100. Watt K.D.S., Pedersen R.A., Kremers W.K., et al. Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study. Am J Transplant 2010, 10:1420-1427.
101. Desai S., Hong J.C., Saab S. Cardiovascular risk factors following orthotopic liver transplantation: predisposing factors, incidence and management. Liver Int 2010, 30:948-957.
102. Aydinalp A., Atar I., Bal U., et al. Determinants of coronary artery disease in liver transplant candidates. Exp Clin Transplant 2010, 8:142-145.
103. Tiukinhoy-Laing S.D., Rossi J.S., Bayram M., et al. Cardiac hemodynamic and coronary angiographic characteristics of patients being evaluated for liver transplantation. Am J Cardiol 2006, 98:178-181.
104. De Marco M., Chinali M., Romano C., et al. Increased left ventricular mass in pre-liver transplantation cirrhotic patients. J Cardiovasc Med (Hagerstown) 2008, 9:142-146.
105. Pozzi M., Carugo S., Boari G., et al. Evidence of functional and structural cardiac abnormalities in cirrhotic patients with and without ascites. Hepatology 1997, 26:1131-1137.
106. Imagawa D.K., Dawson S., Holt C.D., et al. Hyperlipidemia after liver transplantation: natural history and treatment with the hydroxy-methylglutaryl-coenzyme A reductase inhibitor pravastatin. Transplantation 1996, 62:934-942.
107. Guckelberger O., Byram A., Klupp J., et al. Coronary event rates in liver transplant recipients reflect the increased prevalence of cardiovascular risk-factors. Transpl Int 2005, 18:967-974.
108. Zachoval R., Gerbes A.L., Schwandt P., et al. Short-term effects of statin therapy in patients with hyperlipoproteinemia after liver transplantation: results of a randomized cross-over trial. J Hepatol 2001, 35:86-91.
109. Oufroukhi L., Kamar N., Muscari F., et al. Predictive factors for posttransplant diabetes mellitus within one-year of liver transplantation. Transplantation 2008, 85:1436-1442.
110. Laish I., Braun M., Mor E., et al. Metabolic syndrome in liver transplant recipients: prevalence, risk factors, and association with cardiovascular events. Liver Transpl 2011, 17:15-22.
111. Kawaguchi T., Taniguchi E., Itou M., et al. Insulin resistance and chronic liver disease. World J Hepatol 2011, 3:99-107.
112. Larsen J.L., Colling C.W., Ratanasuwan T., et al. Pancreas transplantation improves vascular disease in patients with type 1 diabetes. Diabetes Care 2004, 27:1706-1711.
113. Long-term (5years) efficacy and safety of pancreas transplantation alone in type 1 diabetic patients. Transplantation 2012, 93:842-846.
114. Studer S.M., Levy R.D., McNeil K., et al. Lung transplant outcomes: a review of survival, graft function, physiology, health-related quality of life and cost-effectiveness. Eur Respir J 2004, 24:674-685.
115. Hertz M.I., Taylor D.O., Trulock E.P., et al. The registry of the international society for heart and lung transplantation: nineteenth official report-2002. J Heart Lung Transplant 2002, 21:950-970.
116. Silverborn M., Jeppsson A., Mårtensson G., et al. New-onset cardiovascular risk factors in lung transplant recipients. J Heart Lung Transplant 2005, 24:1536-1543.
117. Bloom R.D., Doyle A.M. Kidney disease after heart and lung transplantation. Am J Transplant 2006, 6:671-679.
118. Taylor D.O., Edwards L.B., Boucek M.M., et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult heart transplant report-2007. J Heart Lung Transplant 2007, 26:769-781.
119. Costanzo M.R., Dipchand A., Starling R., et al. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant 2010, 29:914-956.
120. Zuckermann A., Keogh A., Crespo-Leiro M.G., et al. Randomized controlled trial of sirolimus conversion in cardiac transplant recipients with renal insufficiency. Am J Transplant 2012, 12:2487-2497.
121. Kushwaha S.S., Khalpey Z., Frantz R.P., et al. Sirolimus in cardiac transplantation: use as a primary immunosuppressant in calcineurin inhibitor-induced nephrotoxicity. J Heart Lung Transplant 2005, 24:2129-2136.
122. Eisen H.J., Tuzcu E.M., Dorent R., et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003, 349:847-858.
123. Mancini D., Pinney S., Burkhoff D., et al. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation 2003, 108:48-53.